Caris Life Sciences Q1 revenue rises on demand for molecular profiling services

Caris Life Sciences

07/05/2026 21:52

Overview

Precision medicine firm's Q1 revenue rose 79% yr/yr, driven by molecular profiling services

Gross margin improved to 65% from 47%

Company reaffirmed 2026 revenue guidance and highlighted new product launches

Outlook

Caris Life Sciences reaffirms 2026 revenue guidance of $1.0 bln to $1.02 bln

Company maintains 2026 clinical therapy selection volume growth guidance of about 20%

Result Drivers

MOLECULAR PROFILING GROWTH - Revenue growth driven by 85% increase in molecular profiling services, supported by higher clinical case volume and ASP improvements

SALES FORCE RE-ALIGNMENT - Company said January sales force re-alignment contributed to record performance in February and March

IMPROVED REIMBURSEMENT - Improved reimbursement from molecular profiling services drove operating cash flow improvement

Company press release: ID:nPn9ZdkFqa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$216.17 mln
Q1 Net Income
-$510,000
Q1 Income From Operations
$5.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Caris Life Sciences Inc is $30.00, about 56.8% above its May 6 closing price of $19.13

The stock recently traded at 87 times the next 12-month earnings vs. a P/E of 103 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)